The role of HLA antibodies in allogeneic SCT: Is the type-and-screen strategy necessary not only for blood type but also for HLA

Bone Marrow Transplantation

Volumn 47, Issue 12, 2012, Pages 1499-1506

  Yoshihara, S ^a   Taniguchi, K ^a   Ogawa, H ^a   Saji, H ^b  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Japanese Red Cross Kanto Koshinetsu Block Blood Center   (Japan)

Author keywords

cord blood transplantation; graft failure; haploidentical transplantation; HLA antibodies; solid phase immunoassays

Indexed keywords

BORTEZOMIB; ECULIZUMAB; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; RITUXIMAB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; BLOOD GROUP TYPING; CELL ASSAY; CORD BLOOD STEM CELL TRANSPLANTATION; CROSS REACTION; DISEASE ASSOCIATION; DONOR SELECTION; DRUG MEGADOSE; ENGRAFTMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; FLOW CYTOMETRY; GRAFT FAILURE; GRAFT REJECTION; HLA TYPING; HUMAN; LYMPHOCYTOTOXICITY; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; THROMBOCYTE TRANSFUSION; UNRELATED DONORS;

ABO BLOOD-GROUP SYSTEM; ANIMALS; ANTIBODIES; BLOOD GROUPING AND CROSSMATCHING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; TISSUE DONORS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84870854629     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.249     Document Type: Review

References (72)

1. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008; 142: 348-360
2. Middelburg RA, van Stein D, Briet E, van der Bom JG. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion 2008; 48: 2167-2176.
3. Reil A, Keller-Stanislawski B, Gunay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang 2008; 95: 313-317.
4. Keller-Stanislawski B, Reil A, Gunay S, Funk MB. Frequency and severity of transfusion-related acute lung injury-German haemovigilance data (2006-2007). Vox Sang 2010; 98: 70-77.
5. Shaz BH, Stowell SR, Hillyer CD. Transfusion-related acute lung injury: from bedside to bench and back. Blood 2011; 117: 1463-1471.
6. Barge AJ, Johnson G, Witherspoon R, Torok-Storb B. Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood 1989; 74: 1477-1480.
7. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197-204.
8. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
9. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs risk. Am J Transplant 2003; 3: 1488-1500.
10. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 2008; 86: 377-383.
11. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008; 86: 1754-1761.
12. Caro-Oleas JL, Gonzalez-Escribano MF, Gonzalez-Roncero FM, Acevedo-Calado MJ, Cabello-Chaves V, Gentil-Govantes MA et al. Clinical relevance of HLA donorspecific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transplant 2012; 27: 1231-1238.
13. Maslanka K, Michur H, Zupanska B, Uhrynowska M, Nowak J. Leucocyte antibodies in blood donors and a look back on recipients of their blood components. Vox Sang 2007; 92: 247-249.
14. Powers A, Stowell CP, Dzik WH, Saidman SL, Lee H, Makar RS. Testing only donors with a prior history of pregnancy or transfusion is a logical and cost-effective transfusion-related acute lung injury prevention strategy. Transfusion 2008; 48: 2549-2558.
15. Triulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009; 49: 1825-1835.
16. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, van Dijk BA, van Putten WL, Claas FH et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995; 85: 824-828.
17. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861-1869.
18. van de Watering L, Hermans J, Witvliet M, Versteegh M, Brand A. HLA and RBC immunization after filtered and buffy coat-depleted blood transfusion in cardiac surgery: a randomized controlled trial. Transfusion 2003; 43: 765-771.
19. Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004; 103: 333-339.
20. Sparrow RL, Williams N. The pattern of HLA-DR and HLA-DQ antigen expression on clonable subpopulations of human myeloid progenitor cells. Blood 1986; 67: 379-384
21. Piacibello W, Aglietta M, Stacchini A, Spinelli P, Salvetti L, Kerim S et al. Expression of HLA class II determinants by normal and chronic myeloid leukemia progenitors. Leuk Res 1987; 11: 285-290.
22. Ottmann OG, Nocka KH, Moore MA, Pelus LM. Differential expression of class II MHC antigens in subpopulations of human hematopoietic progenitor cells. Leukemia 1988; 2: 677-686.
23. Aglietta M, Piacibello W, Stacchini A, Dezza L, Sanavio F, Malavasi F et al. Expression of HLA class II (DR, DQ) determinants by normal and chronic myeloid leukemia granulocyte/monocyte progenitors. Cancer Res 1986; 46(Part 1): 1783-1787.
24. Amatruda 3rd TT, Bohman R, Ranyard J, Koeffler HP. Pattern of expression of HLA-DR and HLA-DQ antigens and mRNA in myeloid differentiation. Blood 1987; 69: 1225-1236.
25. Diedrichs-Mohring M, Epplen JT, Schendel DJ. Enhanced expression of HLA-class II molecules on activated human T lymphocytes following treatment with tumor necrosis factor alpha. Hum Immunol 1991; 31: 286-292.
26. Cai J, Terasaki PI, Mao Q, Pham T, El-Awar N, Lee JH et al. Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens. Am J Transplant 2006; 6: 2947-2954.
27. Rodey GE, Fuller TC. Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol 1987; 7: 229-267.
28. Rodey GE, Neylan JF, Whelchel JD, Revels KW, Bray RA. Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994; 39: 272-280.
29. Piazza A, Poggi E, Ozzella G, Borrelli L, Monaco PI, Scornajenghi A et al. Public epitope specificity of HLA class I antibodies induced by a failed kidney transplant: alloantibody characterization by flow cytometric techniques. Transplantation 2006; 81: 1298-1305.
30. Maruya E, Sasaki N, El-Awar N, Akaza T, Kitawaki J, Saji H et al. Immunogenic HLA class I epitopes identified by humoral response to pregnancies. Clin Transpl 2008. 215-227.
31. El-Awar N, Terasaki PI, Nguyen A, Sasaki N, Morales-Buenrostro LE, Saji H et al. Epitopes of HLA antibodies found in sera of normal healthy males and cord blood. Clin Transpl 2008, 199-214.
32. El-Awar N, Terasaki PI, Nguyen A, Sasaki N, Morales-Buenrostro LE, Saji H et al. Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol 2009; 70: 844-853.
33. Alberu J, Morales-Buenrostro LE, de Leo C, Vargas-Rojas MI, Marino-Vazquez LA, Crispin JC. A non-allogeneic stimulus triggers the production of de novo HLA antibodies in healthy adults. Transpl Immunol 2007; 18: 166-171.
34. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J. Natural00 human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86: 1111-1115.
35. Cai J, Terasaki PI, Anderson N, Lachmann N, Schonemann C. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation 2009; 88: 226-230.
36. Nagata S, Okano S, Yonemitsu Y, Nakagawa K, Tomita Y, Yoshikai Y et al. Critical roles of memory T cells and antidonor immunoglobulin in rejection of allogeneic bone marrow cells in sensitized recipient mice. Transplantation 2006; 82: 689-698.
37. Xu H, Chilton PM, Tanner MK, Huang Y, Schanie CL, Dy-Liacco M et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood 2006; 108: 3611-3619.
38. Taylor PA, Ehrhardt MJ, Roforth MM, Swedin JM, Panoskaltsis-Mortari A, Serody JS et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 2007; 109: 1307-1315.
39. Storb R. B cells versus T cells as primary barrier to hematopoietic engraftment in allosensitized recipients. Blood 2009; 113: 1205.
40. Storb R, Floersheim GL, Weiden PL, Graham TC, Kolb HJ, Lerner KG et al. Effect of prior blood transfusions on marrow grafts: abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol 1974; 112: 1508-1516.
41. Weiden PL, Storb R, Slichter S, Warren RP, Sale GE. Effect of six weekly transfusions on canine marrow grafts: tests for sensitization and abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol 1976; 117: 143-150.
42. Gutman JA, McKinney SK, Pereira S, Warnock SL, Smith AG, Woolfrey AE et al. Prospective monitoring for alloimmunization in cord blood transplantation: 00virtual crossmatch00 can be used to demonstrate donor-directed antibodies. Transplantation 2009; 87: 415-418.
43. Takanashi M, Fujiwara K, Tanaka H, Satake M, Nakajima K. The impact of HLA antibodies on engraftment of unrelated cord blood transplants. Transfusion 2008; 48: 791-793.
44. Takanashi M, Atsuta Y, Fujiwara K, Kodo H, Kai S, Sato H et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010; 116: 2839-2846.
45. Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B, Armand P et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011; 118: 6691-6697.
46. Brunstein CG, Noreen H, Defor TE, Maurer D, Miller JS, Wagner JE. Anti-HLA antibodies in double umbilical cord blood transplantation. Biol Blood Marrow Transplant 2011; 17: 1704-1708.
47. Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 2009; 88: 1019-1024.
48. Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 2012; 47: 508-515.
49. Kawase T, Matsuo K, Kashiwase K, Inoko H, Saji H, Ogawa S et al. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 2009; 113: 2851-2858.
50. Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99: 4200-4206.
51. Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998; 339: 1177-1185.
52. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104: 1923-1930.
53. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. Highresolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-4583.
54. Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 2010; 115: 2704-2708.
55. Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P et al. Donor-specific anti-HLA antibodies and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 2011; 118: 5957-5964.
56. Kataoka K, Yamamoto G, Nannya Y, Yoshimi A, Okada S, Asai T et al. Successful engraftment following HLA-mismatched cord blood transplantation for patients with anti-HLA Abs. Bone Marrow Transplant 2008; 42: 129-130.
57. Uchiyama M, Ikeda T. Successful engraftment following umbilical cord blood transplantation for patients with HLA antibody with or without corresponding HLA in the transplanted cord blood. Bone Marrow Transplant 2010; 45: 199-200.
58. Maruta A, Fukawa H, Kanamori H, Harano H, Noguchi T, Kodama F et al. Donor-HLA-incompatible marrow transplantation with an anti-donor cytotoxic antibody in the serum of the patient. Bone Marrow Transplant 1991; 7: 397-400.
59. Pollack MS, Ririe D. Clinical significance of recipient antibodies to stem cell donor mismatched class I HLA antigens. Hum Immunol 2004; 65: 245-247.
60. Costa LJ, Moussa O, Bray RA, Stuart RK. Overcoming HLA-DPB1 donor specific antibody-mediated haematopoietic graft failure. Br J Haematol 2010; 151: 94-96.
61. Narimatsu H, Wake A, Miura Y, Tanaka H, Matsumura T, Takagi S et al. Successful engraftment in crossmatch-positive HLA-mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusion. Bone Marrow Transplant 2005; 36: 555-556
62. Raghavan R, Jeroudi A, Achkar K, Gaber AO, Patel SJ, Abdellatif A. Bortezomib in kidney transplantation. J Transplant 2010; 2010: Article ID 698594.
63. Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010; 15: 8-10.
64. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43: 1460-1480.
65. Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 1073-1084.
66. Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol 2008; 36: 1-8.
67. Mizutani K, Terasaki P, Rosen A, Esquenazi V, Miller J, Shih RN et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 2265-2272.
68. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408-415.
69. Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH et al. Relapec risk after umbilical cord blood transplantation: enhanced graft-versusleukemia effect in recipients of 2 units. Blood 2009; 114: 4293-4299.
70. Lapierre V, Auperin A, Tayebi H, Chabod J, Saas P, Michalet M et al. Increased presence of anti-HLA antibodies early after allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood hematopoietic stem cell transplantation compared with bone marrow transplantation. Blood 2002; 100: 1484-1489.
71. Nakazawa Y, Saito S, Hasegawa Y, Yanagisawa R, Sakashita K, Kamijo T et al. A possible role for the production of multiple HLA antibodies in fatal platelet transfusion refractoriness after peripheral blood progenitor cell transplantation from the mother in a patient with relapsed leukemia. Transfusion 2007; 47: 326-334.
72. Hatakeyama N, Hori T, Yamamoto M, Inazawa N, Iesato K, Miyazaki T et al. Platelet transfusion refractoriness attributable to HLA antibodies produced by donor-derived cells after allogeneic bone marrow transplantation from one HLA-antigen-mismatched mother. Pediatr Transplant 2011; 15: E177-E182.